Bladder cancer
INACTIVE --- New hope for patients progressing after first-line treatment for mUCa

Jeffrey (68 years old)

Jeffrey, 68 years old, dreams of travelling around the world. He has never set foot outside of his own country. Too bad he is afraid of airplanes and easily gets car and seasick.

He has a history of refractory inflammatory bowel disease. Five months ago, he was diagnosed with UCa of the bladder metastatic to the lungs and treated with gemcitabine + cisplatin. He is clear that he does not wish further chemotherapy or immunotherapy, given his inflammatory bowel disease and asks about alternative targeted therapies. The patient consults today.

Assessment summary:

  • ECOG PS: 1
  • CT scan reveals new and enlarging lung lesions
  • FGFR2/3 mutation status in diagnostic biopsy specimen: activating FGFR3 mutation

Which treatment option would you choose for this patient?